Jennifer L Jones1, Gilaad G Kaplan2, Laurent Peyrin-Biroulet3, Leonard Baidoo4, Shane Devlin2, Gil Y Melmed5, Divine Tanyingoh2, Laura Raffals6, Peter Irving7, Patricia Kozuch8, Miles Sparrow9, Fernando Velayos10, Brian Bressler11, Adam Cheifetz12, Jean-Frederic Colombel13, Corey A Siegel14. 1. Dalhousie University, Halifax, Canada. 2. University of Calgary, Calgary, Canada. 3. Inserum U954 and Université de Lorraine, Nancy, France. 4. University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Cedars-Sinai Medical Center, Los Angeles, California. 6. Mayo Clinic, Rochester, Minnesota. 7. Guy's and St Thomas' Hospitals, London, United Kingdom. 8. Jefferson University, Philadelphia, Pennsylvania. 9. The Alfred Hospital, Melbourne, Australia. 10. University of California San Francisco, San Francisco, California. 11. University of British Columbia, Vancouver, Canada. 12. Beth Israel Deaconess Medical Center, Boston, Massachusetts. 13. Icahn School of Medicine at Mount Sinai, New York, New York. 14. Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Electronic address: corey.a.siegel@hitchcock.org.
Abstract
BACKGROUND & AIMS: There is debate over whether patients with Crohn's disease who start anti-tumor necrosis factor (TNF) therapy after failed immunomodulator therapy should continue to receive concomitant immunomodulators. We conducted a meta-analysis of subgroups from randomized controlled trials (RCTs) of anti-TNF agents to compare the efficacy and safety of concomitant immunomodulator therapy vs anti-TNF monotherapy. METHODS: We performed a systematic review of literature published from 1980 through 2008 and identified 11 RCTs of anti-TNF agents in patients with luminal or fistulizing Crohn's disease. We excluded RCTs of patients who were naive to anti-TNF and immunomodulator therapy. The primary end points were clinical response at weeks 4-14 and 24-30 and remission at weeks 24-30. Secondary end points included infusion site or injection site reactions and selected adverse events. A priori subgroup analyses were performed to evaluate fistula closure and the efficacy and safety of combination therapy with different anti-TNF agents. RESULTS: Overall, combination therapy was no more effective than monotherapy in inducing 6-month remission (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.80-1.31), inducing a response (OR, 1.08; 95% CI, 0.79-1.48), maintaining a response (OR, 1.53; 95% CI, 0.67-3.49), or inducing partial (OR, 1.25; 95% CI, 0.84-1.88) or complete fistula closure (OR, 1.10; 95% CI, 0.68-1.78). In subgroup analyses of individual anti-TNF agents, combination therapy was not more effective than monotherapy in inducing 6-month remission in those treated with infliximab (OR, 1.73; 95% CI, 0.97-3.07), adalimumab (OR, 0.88; 95% CI, 0.58-1.35), or certolizumab (OR, 0.93; 95% CI, 0.65-1.34). Overall, combination therapy was not associated with an increase in adverse events, but inclusion of infliximab was associated with fewer injection site reactions (OR, 0.46; 95% CI, 0.26-0.79.) CONCLUSIONS: On the basis of a meta-analysis, continued use of immunomodulator therapy after starting anti-TNF therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission. RCTs are needed to adequately assess the efficacy of continued immunomodulator therapy after anti-TNF therapy is initiated.
BACKGROUND & AIMS: There is debate over whether patients with Crohn's disease who start anti-tumor necrosis factor (TNF) therapy after failed immunomodulator therapy should continue to receive concomitant immunomodulators. We conducted a meta-analysis of subgroups from randomized controlled trials (RCTs) of anti-TNF agents to compare the efficacy and safety of concomitant immunomodulator therapy vs anti-TNF monotherapy. METHODS: We performed a systematic review of literature published from 1980 through 2008 and identified 11 RCTs of anti-TNF agents in patients with luminal or fistulizing Crohn's disease. We excluded RCTs of patients who were naive to anti-TNF and immunomodulator therapy. The primary end points were clinical response at weeks 4-14 and 24-30 and remission at weeks 24-30. Secondary end points included infusion site or injection site reactions and selected adverse events. A priori subgroup analyses were performed to evaluate fistula closure and the efficacy and safety of combination therapy with different anti-TNF agents. RESULTS: Overall, combination therapy was no more effective than monotherapy in inducing 6-month remission (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.80-1.31), inducing a response (OR, 1.08; 95% CI, 0.79-1.48), maintaining a response (OR, 1.53; 95% CI, 0.67-3.49), or inducing partial (OR, 1.25; 95% CI, 0.84-1.88) or complete fistula closure (OR, 1.10; 95% CI, 0.68-1.78). In subgroup analyses of individual anti-TNF agents, combination therapy was not more effective than monotherapy in inducing 6-month remission in those treated with infliximab (OR, 1.73; 95% CI, 0.97-3.07), adalimumab (OR, 0.88; 95% CI, 0.58-1.35), or certolizumab (OR, 0.93; 95% CI, 0.65-1.34). Overall, combination therapy was not associated with an increase in adverse events, but inclusion of infliximab was associated with fewer injection site reactions (OR, 0.46; 95% CI, 0.26-0.79.) CONCLUSIONS: On the basis of a meta-analysis, continued use of immunomodulator therapy after starting anti-TNF therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission. RCTs are needed to adequately assess the efficacy of continued immunomodulator therapy after anti-TNF therapy is initiated.
Authors: Edward L Barnes; Alison Goldin; Rachel W Winter; Emily Collins; Bonnie Cao; Madeline Carrellas; Anne Marie Crowell; Joshua R Korzenik Journal: Dig Dis Sci Date: 2016-09-17 Impact factor: 3.199
Authors: A N Ananthakrishnan; A Sakuraba; E L Barnes; J Pekow; L Raffals; M D Long; R S Sandler Journal: Aliment Pharmacol Ther Date: 2017-05-03 Impact factor: 8.171
Authors: Abhinav Vasudevan; Ajay Raghunath; Shane Anthony; Cian Scanlon; Miles P Sparrow; Peter R Gibson; Daniel R van Langenberg Journal: Dig Dis Sci Date: 2018-12-17 Impact factor: 3.199
Authors: Soon Man Yoon; Talin Haritunians; Sultan Chhina; Zhenqiu Liu; Shaohong Yang; Carol Landers; Dalin Li; Byong Duk Ye; David Shih; Eric A Vasiliauskas; Andrew Ippoliti; Shervin Rabizadeh; Stephan R Targan; Gil Y Melmed; Dermot P B McGovern Journal: Inflamm Bowel Dis Date: 2017-08 Impact factor: 5.325
Authors: Mark T Osterman; William J Sandborn; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Anne M Robinson; Qian Zhou; James D Lewis Journal: Am J Gastroenterol Date: 2016-09-27 Impact factor: 10.864